Enterprise Value
-76.08M
Cash
214.8M
Avg Qtr Burn
-11.41M
Short % of Float
4.41%
Insider Ownership
9.96%
Institutional Own.
64.33%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
TEMBEXA (brincidofovir) Details Smallpox | Approved Quarterly sales | |
ONC201 Details Glioblastoma, Cancer, Glioma | Phase 3 Data readout | |
ONC206 Details Brain tumor, Solid tumor/s | Phase 1 Data readout | |
Dociparstat sodium (DSTAT) Details Cancer, Acute myeloid leukemia | Failed Discontinued | |
Dociparstat sodium (DSTAT) Details Infectious disease, COVID-19 | Failed Discontinued |